Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.

James, N D; Sydes, M R; Clarke, N W; Ritchie, A W S; Parmar, M K B

Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.

James, N D; Sydes, M R; Clarke, N W; Ritchie, A W S; Parmar, M K B.

Afiliação

James ND; Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
Sydes MR; MRC Clinical Trials Unit at UCL, London, UK.
Clarke NW; Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
Ritchie AW; MRC Clinical Trials Unit at UCL, London, UK.
Parmar MK; MRC Clinical Trials Unit at UCL, London, UK.

Clin Oncol (R Coll Radiol) ; 28(10): 666-7, 2016 10.

Article em En | MEDLINE | ID: mdl-27477123

Assuntos

Neoplasias da Próstata; Taxoides; Protocolos de Quimioterapia Combinada Antineoplásica; Docetaxel; Humanos; Masculino; Neutropenia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Taxoides Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Clin Oncol (R Coll Radiol) Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google